Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Executive Briefing – China's revolution in the making

This article was originally published in Scrip

Executive Summary

An analysis of the Chinese healthcare market in 2007 highlights its many contradictions. On the one hand, it grew by an astonishing 25.5% compared with the previous year,1 surpassing growth figures for most developed countries. By the end of last year, the Chinese market was valued at Yuan633.8 billion ($86.8 billion). Yet on the other hand, China is still grappling with serious problems, such as high drug prices; poor medical insurance coverage, especially in rural Chinese and migrant populations; fake and/or unsafe drugs; and a rather complicated (and constantly changing) regulatory environment. Against this backdrop, no other industry has drawn quite as much criticism in China as healthcare.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts